Valuation: Biolidics Limited

Market Cap 67.6M 52.67M 45.71M 42.8M 39.15M 73.92M 5.02B 74.88M 501M 197M 2.51B 198M 193M 8.34B P/E 2024
-8.18x
P/E 2025 -22.5x
Enterprise Value 69.46M 54.12M 46.97M 43.98M 40.23M 75.95M 5.16B 76.94M 514M 202M 2.58B 203M 199M 8.57B EV / Sales 2024
58.8x
EV / Sales 2025 17.5x
Free-Float
44.94%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
President 46 2024-04-29
Comptroller/Controller/Auditor 44 2024-06-30
Corporate Secretary - -
Director TitleAgeSince
Director/Board Member 64 2021-06-13
Director/Board Member 55 2023-03-30
Director/Board Member 70 2023-11-26
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 47.36M
-0.39%-0.27%+28.13%+4.25% 214B
-0.55%+1.05%+1.57%-22.45% 140B
-0.42%+5.85%-21.19%+20.82% 133B
+3.40%+7.42%-52.00%-2.59% 69.19B
+0.11%+2.44%+13.27%+11.52% 51.28B
-0.36%+5.11%-14.27%-19.86% 50.43B
-0.25%+1.33%+24.13%+11.10% 39.85B
-1.01%+4.11%+42.57%+36.66% 39.27B
-0.10%+7.62%-19.97%+20.24% 32.32B
Average +0.08%+3.77%+0.25%+6.63% 85.43B
Weighted average by Cap. -0.02%+3.04%+2.30%+3.20%

Financials

2024 2025
Net sales 858K 669K 580K 543K 497K 938K 63.68M 950K 6.36M 2.49M 31.82M 2.51M 2.46M 106M 5.26M 4.1M 3.56M 3.33M 3.05M 5.75M 390M 5.83M 38.97M 15.29M 195M 15.39M 15.06M 649M
Net income -3.43M -2.68M -2.32M -2.17M -1.99M -3.75M -255M -3.8M -25.44M -9.98M -127M -10.05M -9.83M -424M -3.96M -3.09M -2.68M -2.51M -2.29M -4.33M -294M -4.39M -29.35M -11.52M -147M -11.59M -11.34M -489M
Net Debt 1.46M 1.13M 984K 921K 843K 1.59M 108M 1.61M 10.78M 4.23M 53.96M 4.26M 4.16M 180M 1.86M 1.45M 1.25M 1.18M 1.07M 2.03M 138M 2.06M 13.75M 5.4M 68.83M 5.43M 5.31M 229M
Logo Biolidics Limited
Biolidics Limited is a Singapore-based precision medicine medical technology company. The Company's principal activities are technology development, technology transfer, selling and distribution of biomedical technology, life and medicine science related products and services; provision of laboratory services and investment holding. Its segments are Cancer, Infectious diseases, and Laboratory services, and Corporate segments. Its Cancer and infectious diseases segments involve the identifying and assessing potential collaboration partners, technology, products and services, product development, innovation and improvement and the management of global distributorship networks and direct customers in the cancer field, and the infectious diseases field. The Laboratory services segment involves the business, operation, and provision of laboratory services to customers. The laboratory has regulatory approval from Singapore’s Ministry of Health for testing for COVID-19 in Singapore.
Employees
-